Investigating the role of Tribbles 2 in prostate cancer after anti-androgen therapy
Official title: Neuroendocrine differentiation post anti-androgenic therapy: Role of Tribbles 2
Funded at Henry Ford Health System · NIH-11056750 · Data updated 2026-11-12
This study is looking at how prostate cancer cells stop responding to treatments like enzalutamide, and it aims to find new ways to tackle these tough cells by focusing on a protein called Tribbles 2, which might help them grow and resist treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health System NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project start | April 20, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $347,700 |
| NIH project number | 5R01CA269635-03 |
| Project ID | NIH-11056750 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with prostate cancer who have developed resistance to anti-androgen therapies.
✕Less likely to help
Patients with early-stage prostate cancer who have not yet undergone anti-androgen therapy may not benefit from this research.
What this research studies
This research focuses on understanding how prostate cancer cells become resistant to anti-androgen therapies like enzalutamide. By creating models that mimic the conditions of patients undergoing treatment, researchers are analyzing gene expression to identify critical molecular targets. The study specifically examines the role of Tribbles 2, a protein that appears to contribute to cancer cell growth and resistance. If successful, this research could lead to new therapies that effectively target resistant prostate cancer cells.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with enzalutamide-resistant prostate cancer.
How similar studies have gone: Other research has shown promise in targeting molecular pathways in resistant prostate cancer, suggesting that this approach could yield significant insights.
Where this research is happening
-
Henry Ford Health System
Detroit, United States Active
Researchers
- Principal investigator: Ghosh, Jagadananda — Henry Ford Health System
- Study coordinator: Ghosh, Jagadananda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.